Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- AMRI Sees '07 Contract Revenue Of $41 Million, Milestone Revenue $165 Million
Jan 29, 2008 09:02 AM
- AMRI Sees '07 Contract Revenue Of $41 Million, Milestone Revenue $165 Million
Jan 29, 2008 09:02 AM
- AMRI Sees '07 Contract Revenue Of $41 Million, Milestone Revenue $165 Million
Jan 29, 2008 09:02 AM
- AMRI Sees 4Q Contract, Milestone Revenue Of $41 Million
Jan 29, 2008 09:02 AM
- AMRI Sees 4Q Contract, Milestone Revenue Of $41 Million
Jan 29, 2008 09:02 AM
- Albany Molecular Gets Payment From Bristol-Myers Licensing Pact
Jun 11, 2007 09:08 AM
- Albany Molecular Gets Payment From Bristol-Myers Licensing Pact
Jun 11, 2007 09:08 AM
- Albany Molecular, Bristol-Myers In 2-Year Drug Devt Pact
Dec 21, 2006 09:30 AM
- Albany Molecular, Bristol-Myers In 2-Year Drug Devt Pact
Dec 21, 2006 09:30 AM
- Albany Molecular Swings To 2Q Loss On Charge;Revenue Falls
Aug 02, 2006 09:58 AM
- AMRI Announces Agreement with Teva Pharmaceuticals and Barr
Laboratories to Settle Litigation in ALLEGRA® and
ALLEGRA®D-12 U.S. Patent Dispute
Nov 19, 2008 01:31 AM
- AMRI Announces Third Quarter 2008 Results
Nov 05, 2008 05:02 PM
- AMRI Presents Preclinical Data for Tubulin Inhibitor, ALB109564(a), at EORTC-NCI-AACR Symposium
Oct 30, 2008 09:26 AM
- AMRI to Announce Third Quarter Results
Oct 30, 2008 08:09 AM
- AMRI Expands Manufacturing Capabilities in India; Adds Non-GMP Plant Capacity
Oct 29, 2008 08:09 AM
- AMRI Appoints New Chemistry Director of European Operations
Sep 30, 2008 09:12 AM
- AMRI to Present at the UBS 2008 Global Life Sciences Conference
Sep 18, 2008 08:06 AM
- Second Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
Sep 08, 2008 07:01 AM
- AMRI Announces Leadership Changes in Pharmaceutical Development and Manufacturing
Sep 03, 2008 04:32 PM
- AMRI Initiates Phase I Study of Proprietary Oncology Drug Candidate
Aug 18, 2008 09:17 AM
- Form 4 Hagen Steven R For: Nov 20 (10K)
Nov 21, 2008 03:06 PM
- Form 4 TARTAGLIA ANTHONY P For: Nov 20 (10K)
Nov 21, 2008 03:00 PM
- Form 4 ANDERSON PAUL S For: Nov 20 (10K)
Nov 21, 2008 02:57 PM
- Form 4 ALBANY MOLECULAR RESEARC For: Nov 20 Filed by: ROTH ARTHUR J (10K)
Nov 21, 2008 02:56 PM
- Form 4 OCONNOR KEVIN For: Nov 20 (10K)
Nov 21, 2008 02:56 PM
- Form 4 KUHLA DONALD E For: Nov 20 (10K)
Nov 21, 2008 02:56 PM
- Form 4 Jordan Veronica GH For: Nov 20 (10K)
Nov 21, 2008 02:56 PM
- Form 4 Hagen Steven R For: Nov 17 (10K)
Nov 19, 2008 03:52 PM
- Form 4 ALBANY MOLECULAR RESEARC For: Nov 05 Filed by: D AMBRA CONSTANCE M (10K)
Nov 07, 2008 12:06 PM
- Form 4 ALBANY MOLECULAR RESEARC For: Nov 05 Filed by: D AMBRA THOMAS E PHD (10K)
Nov 07, 2008 12:06 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
AMRI
|
Compare to S&P
|
| YTD |
-34.01 %
|
8.12 %
|
| 4 Weeks |
-24.98 %
|
-18.91 %
|
| 12 Weeks |
-46.35 %
|
-25.64 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -25.00 %
|
|
EPS Growth in Last Year: 200.00 %
|
|
Sales Growth in Last Quarter: 5.92 %
|
|
Sales Growth in Last Quarter: 29.03 %
|
|
|
